Their technology is very interesting, and may end up being more advanced than what the other firms are doing with CAR T cell modification. It modifies the signaling proteins that activate or deactivate CAR T cells so that they can be triggered by the small molecule rimiducid to either instigate programmed cell dealth or prolifieration or activation of immune cells. In this way they control the effects of CAR T in the body in real time, which adds a level of safetly not seen in first generation technology. That's pretty cool.
apokerace, if you actually think that magnam has "caused" many people to buy "millions of dollars" of worthless options by "conning" them into inaccurate timelines through a Yahoo message board, then you are one of two things and possibly both: paranoid and/or delusional. And by the way, stop marking every post I make with a thumbs down. What are you, 12?
1. He said this is a "giant" secondary. It's not. It's 10% of shares outstanding.
2. He said, don't buy it right here; if the market goes down then people will give up on this stock." That's all true if you think the valuation is too high. I think it's too low, and the market agrees - they pushed it up past $94 a share and it will go over $100. The $85/share provides a floor on the valuation. Granted, buyers of the secondary may short the stock, but I think, like Receptos, this will take off from here. We'll see.
so the time to test five doses plus the initial 14 day safety trials on healthy volunteers puts us somewhere between Dec 17th and Dec 31.
yeah not so great. Bluebird's is a much better procedure.
good one! You bought in at 40 cents cheaper than the shares I just added to my original holdings. I think we'll see at least $60 if we see $55.
they couldn't have picked a worse day to announce a secondary!
either way doesn't matter unless 3422 is a bomb
I've already set up a contingency fund for a precipitous decline in price, so I can buy at the lows, if that were to occur. Come on, guys! Gilead had a ten year partnership with this company. They bet the farm on Achillion. But then they saw the nuc from Idenix, and they took it, for the highest price ever for a relatively unknown startup, $11 billion. This doesn't mean that Gilead stopped communicating with Achillion, which has been developing HEPC drugs for 17 years. Gilead is all over this. And they will acquire ACHN if they have any brains in their M&A department. ACHN extends Gilead's franchise by 5-15 years.
are you a west coast guy? Because if you are , you're one lucky guy!!!
we should call a board meeting! lol!
ditto that. And if ACHN reports a 6 week 95%+ on 3102, hold on to your side rails. The price is going to take off.
I'll certainly take the 4.7. That's just icing on the cake.
yes, I can. first, I said the NS5A is worth $15 a share. That's $1.5 billion market cap. Gilead's Harvoni is a $95,000 treatment, and is about $11,000 over Sovaldi. At 150,000 people treated per year, Ledipasvir is adding about $1.65 billion to the equation. 3102 so far has performed better than Lidipasvir (100% cure rates on 19 people at 8 weeks).. So my $15 is conservative, to say the least. Second point: Enanta: $800 mill market cap with a PI about the efficacy of sovaprevir. So take 3102, 2684, and sovaprevir. do you not think these three in combination are worth at least $20, or 2+ billion, after what I just said about 3102?
Hi Magnam, I'm still expecting a 3.9-4.5 at 500 mgs. Which I'm fine with, even at the lower figure. I think 3102 will make up any 'absolute' deficiency in 3422 through the synergistic effects. .